Alternative microbiological methods in the pharmaceutical industry: The need for a new microbiology curriculum

American Pharmaceutical Review

Volumn 9, Issue 5, 2006, Pages

  Denoya, Claudio D ^a   Colgan, Stephen T ^a   Du Moulin, Gary C ^b  

^a PFIZER

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPILLARY ELECTROCHROMATOGRAPHY; CELL VIABILITY; DRUG INDUSTRY; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FOOD AND DRUG ADMINISTRATION; GEL ELECTROPHORESIS; GENOME ANALYSIS; GOOD MANUFACTURING PRACTICE; HEALTH PRACTITIONER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL EDUCATION; MICROBIOLOGICAL EXAMINATION; POLYMERASE CHAIN REACTION; PROTEOMICS; QUALITY CONTROL; REVIEW;

EID: 55749116364     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. May, M. Building a better biosensor. The Scientist. 100:36-38, 2004.
2. Sutton S.V.W. "Opportunities for the Pharmaceutical Industry (Chapter 6)" in Encyclopedia of Rapid Microbiological Methods, ed. Miller M., Parenteral Drug Association, Bethesda, MD, pp273-290, 2005.
3. U.S. Pharmacopoeia 〈1223〉 Validation of Alternative Microbiological Methods. USP in Pharmacopoeial Forum, 31:1475- 1486, 2005.
4. European Pharmacopoeia , 5.1.6 Alternative Methods for Control of Microbiological Quality. in PharmEuropa, Suppl. 5.5, 4131-4142.
5. Guidance for Industry PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Office of Regulatory Affairs (ORA), Pharmaceutical CGMPs, September 2004.
6. Nasr, Moheb M., "Risk-Based CMC Review and Quality Assessment: What is Quality by Design (QbD)." 2006 FDA/Industry Conference. School of Pharmacy - Temple University, March 29, 2006.
7. FDA Guidance for Industry, Comparability Protocols - Chemistry, Manufacturing, and Controls Information, issued February 2003.
8. Korcznski, M.S. The Importance of Emerging rapid Methods technology to Regulators and Industry (Chapter 3) " in Encyclopedia of Rapid Microbiological Methods, ed. Miller M., Parenteral Drug Association, Bethesda, MD, pp273-290, 2005.
9. Fung D.Y.C. Rapid Methods and Automation in Microbiology Comprehensive Rev. in Food Science and Food Safety 1:3-22, 2002.
10. du Moulin, GC, Kielpinski G, Prinzi S, Duguid J, and Price A. "Detection of microbial contaminants for cell therapy products: Validation of an automated microbial detection system" in Encyclopedia of Rapid Microbiological Methods, ed. Miller M., Parenteral Drug Association, Bethesda, MD, pp273-290, 2005.
11. Newby P. Obstacles and Opportunities to the Introduction of Pharmaceutical rapid Microbiological Methods" (Chapter 4) in Encyclopedia of Rapid Microbiological Methods, ed. Miller M., Parenteral Drug Association, Bethesda, MD, pp273-290, 2005.
12. Olsen WP, Groves MJ Klegerman ME (1990) Identifying bacterial contaminants in a pharmaceutical manufacturing facility by gas chromatographic fatty acid analysis. Pharm Technol 14:32-36.
13. Eldering JA, Felten C, Veilleux CA, Potts BJ (2004) Development of a PCR method for mycoplasma testing of Chinese hamster ovary cell cultures used in the manufacture of recombinant therapeutic proteins. Biologicals 32:183-193.
14. Miller MJ. Foreword in Encyclopedia of Rapid Microbiological Methods ed. Miller, M., Parenteral Drug Association, Bethesda MD ppxix-xxiv, 2005.